Skip to main content
SpringerLink
Log in

Primary Sclerosing Cholangitis

  • Chapter
Book cover Management of Benign Biliary Stenosis and Injury

  • 825 Accesses

Abstract

Primary sclerosing cholangitis is a chronic and intractably progressive cholangiopathy that leads to the development of fibrotic biliary strictures, cholangitis, biliary cirrhosis and end-stage liver disease. It portends a significant risk of hepatobiliary and colorectal malignancy. The disease is intimately linked with inflammatory bowel disease, and is often regarded as the classic hepatobiliary manifestation of colitis. There are currently no disease-modifying treatments that abrogate the progression to end-stage liver disease, though advances in the understanding of the underlying mechanisms of disease carry hope for improved risk stratification and treatment in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58(6):2045–55.

    Article  PubMed  CAS  Google Scholar 

  2. NA M, Kareemi H, Parab R, et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology. 2011;53(5):1590–9.

    Article  Google Scholar 

  3. Andersen IM, Tengesdal G, Lie BA, Boberg KM, Karlsen TH, Hov JR. Effects of coffee consumption, smoking, and hormones on risk for primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2014;12(6):1019–28.

    Article  PubMed  Google Scholar 

  4. Boonstra K, van Erpecum KJ, van Nieuwkerk KMJ, et al. Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(12):2270–6.

    Article  PubMed  Google Scholar 

  5. Loftus EV, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54(1):91–6.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Schaeffer DF, Win LL, Hafezi-Bakhtiari S, Cino M, Hirschfield GM, El-Zimaity H. The phenotypic expression of inflammatory bowel disease in patients with primary sclerosing cholangitis differs in the distribution of colitis. Dig Dis Sci. 2013;58(9):2608–14.

    Article  PubMed  CAS  Google Scholar 

  7. Portmann B, Zen Y. Inflammatory disease of the bile ducts-cholangiopathies: liver biopsy challenge and clinicopathological correlation. Histopathology. 2012;60(2):236–48. doi:10.1111/j.1365-2559.2011.03853.x.

    Article  PubMed  Google Scholar 

  8. Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. Lancet. 2013;382(9904):1587–99.

    Article  PubMed  Google Scholar 

  9. Borchers AT, Shimoda S, Bowlus C, Keen CL, Gershwin ME. Lymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitis. Semin Immunopathol. 2009;31(3):309–22.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  10. Broomé U, Olsson R, Lööf L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut. 1996;38(4):610–5.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Van den Hazel SJ, Wolfhagen EH, van Buuren HR, van de Meeberg PC, Van Leeuwen DJ. Prospective risk assessment of endoscopic retrograde cholangiography in patients with primary sclerosing cholangitis. Dutch PSC Study Group. Endoscopy. 2000;32(10):779–82.

    Article  PubMed  Google Scholar 

  12. Alkhatib AA, Hilden K, Adler DG. Comorbidities, sphincterotomy, and balloon dilation predict post-ERCP adverse events in PSC patients: operator experience is protective. Dig Dis Sci. 2011;56(12):3685–8.

    Article  PubMed  Google Scholar 

  13. Von Seth E, Arnelo U, Enochsson L, Bergquist A. Primary sclerosing cholangitis increases the risk for pancreatitis after endoscopic retrograde cholangiopancreatography. Liver Int. 2014;10:1–9.

    Google Scholar 

  14. Dave M, Elmunzer BJ, Dwamena BA, Higgins PDR. Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. Radiology. 2010;256(2):387–96.

    Article  PubMed  Google Scholar 

  15. Fulcher AS, Turner MA, Franklin KJ, et al. Primary sclerosing cholangitis: evaluation with MR cholangiography-a case–control study. Radiology. 2000;215(1):71–80.

    Article  PubMed  CAS  Google Scholar 

  16. Chandok N, Hirschfield GM. Management of primary sclerosing cholangitis: conventions and controversies. Can J Gastroenterol. 2012;26(5):261–8.

    PubMed  PubMed Central  Google Scholar 

  17. Meagher S, Yusoff I, Kennedy W, Martel M, Adam V, Barkun A. The roles of magnetic resonance and endoscopic retrograde cholangiopancreatography (MRCP and ERCP) in the diagnosis of patients with suspected sclerosing cholangitis: a cost-effectiveness analysis. Endoscopy. 2007;39(3):222–8.

    Article  PubMed  CAS  Google Scholar 

  18. Talwalkar JA, Angulo P, Johnson CD, Petersen BT, Lindor KD. Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology. 2004;40(1):39–45.

    Article  PubMed  Google Scholar 

  19. Kamisawa T, Funata N, Hayashi Y, et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol. 2003;38(10):982–4. doi:10.1007/s00535-003-1175-y.

    Article  PubMed  CAS  Google Scholar 

  20. Hart PA, Kamisawa T, Brugge WR, et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut. 2013;62(12):1771–6.

    Article  PubMed  PubMed Central  Google Scholar 

  21. De Buy Wenniger LJM, Culver EL, Beuers U. Exposure to occupational antigens might predispose to IgG4-related disease. Hepatology. 2014;60(4):1453–4.

    Article  PubMed  Google Scholar 

  22. Chari ST. Diagnosis of autoimmune pancreatitis using its five cardinal features: introducing the Mayo Clinic’s HISORt criteria. J Gastroenterol. 2007;42 Suppl 1:39–41.

    Article  PubMed  Google Scholar 

  23. Van Heerde MJ, Buijs J, Rauws EA, et al. A comparative study of diagnostic scoring systems for autoimmune pancreatitis. Pancreas. 2014;43(4):559–64.

    Article  PubMed  Google Scholar 

  24. Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134(3):706–15.

    Article  PubMed  Google Scholar 

  25. Björnsson E, Olsson R, Bergquist A, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology. 2008;134(4):975–80.

    Article  PubMed  Google Scholar 

  26. Naess S, Björnsson E, Anmarkrud JA, et al. Small duct primary sclerosing cholangitis without inflammatory bowel disease is genetically different from large duct disease. Liver Int. 2014;34(10):1488–95.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  27. Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology. 2001;33(3):544–53.

    Article  PubMed  CAS  Google Scholar 

  28. Rupp C, Rössler A, Halibasic E, et al. Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis. Aliment Pharmacol Ther. 2014;40(11–12):1292–301.

    Article  PubMed  CAS  Google Scholar 

  29. Paumgartner G, Beuers U. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis. 2004;8(1):67–81. vi.

    Article  PubMed  Google Scholar 

  30. Halilbasic E, Fiorotto R, Fickert P, et al. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2−/− mice. Hepatology. 2009;49(6):1972–81.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  31. Day AP, Feher MD, Chopra R, Mayne PD. The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities. Metabolism. 1993;42(7):839–42.

    Article  PubMed  CAS  Google Scholar 

  32. Färkkilä M, Karvonen A-L, Nurmi H, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology. 2004;40(6):1379–86.

    Article  PubMed  Google Scholar 

  33. Davies YK, Cox KM, Abdullah BA, Safta A, Terry AB, Cox KL. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr. 2008;47(1):61–7.

    Article  PubMed  CAS  Google Scholar 

  34. Pohl J, Ring A, Stremmel W, Stiehl A. The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol. 2006;18(1):69–74.

    Article  PubMed  Google Scholar 

  35. Etzel JP, Eng SC, Ko CW, et al. Complications after ERCP in patients with primary sclerosing cholangitis. Gastrointest Endosc. 2008;67(4):643–8.

    Article  PubMed  Google Scholar 

  36. Rudolph G, Gotthardt D, Klöters-Plachky P, Kulaksiz H, Rost D, Stiehl A. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J Hepatol. 2009;51(1):149–55.

    Article  PubMed  Google Scholar 

  37. Rudolph G, Gotthardt D, Kloeters-Plachky P, Rost D, Kulaksiz H, Stiehl A. In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival. J Hepatol. 2010;53(2):313–7.

    Article  PubMed  Google Scholar 

  38. Kaya M, Petersen BT, Angulo P, et al. Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol. 2001;96(4):1059–66.

    Article  PubMed  CAS  Google Scholar 

  39. Gotthardt DN, Rudolph G, Klöters-Plachky P, Kulaksiz H, Stiehl A. Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment. Gastrointest Endosc. 2010;71(3):527–34.

    Article  PubMed  Google Scholar 

  40. Sinakos E, Saenger AK, Keach J, Kim WR, Lindor KD. Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19–9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol. 2011;9(5):434–9.e1.

    Article  PubMed  CAS  Google Scholar 

  41. Levy MJ, Baron TH, Clayton AC, et al. Prospective evaluation of advanced molecular markers and imaging techniques in patients with indeterminate bile duct strictures. Am J Gastroenterol. 2008;103(5):1263–73.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Kipp BR, Stadheim LM, Halling SA, et al. A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol. 2004;99(9):1675–81.

    Article  PubMed  Google Scholar 

  43. Tischendorf JJW, Meier PN, Schneider A, Manns MP, Krüger M. Transpapillary intraductal ultrasound in the evaluation of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Scand J Gastroenterol. 2007;42(8):1011–7.

    Article  PubMed  CAS  Google Scholar 

  44. Metzger J, Negm AA, Plentz RR, et al. Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut. 2013;62(1):122–30.

    Article  PubMed  CAS  Google Scholar 

  45. Buckles DC, Lindor KD, Larusso NF, Petrovic LM, Gores GJ. In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol. 2002;97(5):1138–42.

    Article  PubMed  Google Scholar 

  46. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237–67.

    Article  Google Scholar 

  47. Angulo P, Grandison GA, Fong DG, et al. Bone disease in patients with primary sclerosing cholangitis. Gastroenterology. 2011;140(1):180–8.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Gores GJ, Darwish Murad S, Heimbach JK, Rosen CB. Liver transplantation for perihilar cholangiocarcinoma. Dig Dis. 2013;31(1):126–9.

    Article  PubMed  Google Scholar 

  49. Cholongitas E, Shusang V, Papatheodoridis GV, et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 2008;14(2):138–43.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Liver Research, NIHR Liver Biomedical Research Unit, University of Birmingham, Birmingham, UK

    Debashis Haldar M.A., M.R.C.P. & Gideon M. Hirschfield Ph.D., F.R.C.P.

  2. Centre for Liver Research, Institute of Biomedical Research, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK

    Gideon M. Hirschfield Ph.D., F.R.C.P.

Authors
  1. Debashis Haldar M.A., M.R.C.P.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gideon M. Hirschfield Ph.D., F.R.C.P.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gideon M. Hirschfield Ph.D., F.R.C.P. .

Editor information

Editors and Affiliations

  1. Foothills Medical Centre, University of Calgary, Calgary, Alberta, Canada

    Elijah Dixon

  2. Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA

    Charles M. Vollmer Jr.

  3. Division of Gastroenterology, St. Michael's Hospital, Toronto, Ontario, Canada

    Gary R. May

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Haldar, D., Hirschfield, G.M. (2015). Primary Sclerosing Cholangitis. In: Dixon, E., Vollmer Jr., C., May, G. (eds) Management of Benign Biliary Stenosis and Injury. Springer, Cham. https://doi.org/10.1007/978-3-319-22273-8_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-22273-8_2

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-22272-1

  • Online ISBN: 978-3-319-22273-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation